Click here for a PDF copy of Hexima’s Annual Financial Report for the year ended June 30 2017.
- Hexima doses first patient in phase 1/2a trial of HXP124 as a novel topical treatment for fungal nail infections
- Recruiting patients for fungal nail study
- VIDEO: CSO Marilyn Anderson interviewed by the AAS.
- Hexima AGM 2017 – Presentations and Results
- Hexima receives approval to conduct a phase 1/2a study for fungal nail infections